Arax Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.32M | Buy |
4,662
+3,239
| +228% | +$1.44M | 0.02% | 783 |
|
|
2026
Q1 | $632K | Sell |
1,423
-553
| -28% | -$258K | 0.02% | 561 |
|
|
2025
Q4 | $896K | Buy |
1,976
+337
| +21% | +$145K | 0.03% | 410 |
|
|
2025
Q3 | $642K | Buy |
1,639
+616
| +60% | +$257K | 0.01% | 814 |
|
|
2025
Q2 | $455K | Sell |
1,023
-5
| -0.5% | -$2.3K | 0.02% | 411 |
|
|
2025
Q1 | $498K | Sell |
1,028
-823
| -44% | -$384K | 0.03% | 317 |
|
|
2024
Q4 | $745K | Buy |
1,851
+1,495
| +420% | +$693K | 0.05% | 217 |
|
|
2024
Q3 | $166K | Buy |
356
+8
| +2% | +$3.84K | 0.01% | 384 |
|
|
2024
Q2 | $163K | Buy |
348
+292
| +521% | +$127K | 0.02% | 368 |
|
|
2024
Q1 | $23.4K | Hold |
56
| – | – | ﹤0.01% | 643 |
|
|
2023
Q4 | $22.8K | Hold |
56
| – | – | ﹤0.01% | 627 |
|
|
2023
Q3 | $19.5K | Hold |
56
| – | – | ﹤0.01% | 587 |
|
|
2023
Q2 | $19.7K | Buy |
56
+5
| +10% | +$1.69K | ﹤0.01% | 588 |
|
|
2023
Q1 | $16.1K | Buy |
51
+13
| +34% | +$3.9K | ﹤0.01% | 618 |
|
|
2022
Q4 | $11K | Buy |
38
+3
| +9% | +$914 | ﹤0.01% | 641 |
|
|
2022
Q3 | $10K | Sell |
35
-10
| -22% | -$2.88K | ﹤0.01% | 669 |
|
|
2022
Q2 | $13K | Buy |
45
+23
| +105% | +$6.16K | ﹤0.01% | 620 |
|
|
2022
Q1 | $6K | Sell |
22
-28
| -56% | -$6.64K | ﹤0.01% | 755 |
|
|
2021
Q4 | $11K | Sell |
50
-15
| -23% | -$2.92K | ﹤0.01% | 642 |
|
|
2021
Q3 | $12K | Buy |
65
+5
| +8% | +$976 | ﹤0.01% | 623 |
|
|
2021
Q2 | $12K | Buy |
+60
| New | +$12.6K | ﹤0.01% | 638 |
|
|
2020
Q4 | $15K | Buy |
64
+4
| +7% | +$918 | ﹤0.01% | 528 |
|
|
2020
Q3 | $16K | Hold |
60
| – | – | ﹤0.01% | 498 |
|
|
2020
Q2 | $17K | Hold |
60
| – | – | ﹤0.01% | 492 |
|
|
2020
Q1 | $14K | Hold |
60
| – | – | ﹤0.01% | 498 |
|
|
2019
Q4 | $13K | Buy |
60
+22
| +58% | +$4.45K | ﹤0.01% | 447 |
|
|
2019
Q3 | $6K | Hold |
38
| – | – | ﹤0.01% | 509 |
|
|
2019
Q2 | $7K | Buy |
+38
| New | +$6.64K | ﹤0.01% | 497 |
|
|
2018
Q4 | $6K | Hold |
38
| – | – | ﹤0.01% | 481 |
|
|
2018
Q3 | $7K | Sell |
38
-22
| -37% | -$3.92K | ﹤0.01% | 505 |
|
|
2018
Q2 | $10K | Sell |
60
-5
| -8% | -$775 | ﹤0.01% | 346 |
|
|
2018
Q1 | $10K | Buy |
65
+27
| +71% | +$4.41K | 0.01% | 328 |
|
|
2017
Q4 | $5K | Sell |
38
-5
| -12% | -$740 | ﹤0.01% | 382 |
|
|
2017
Q3 | $6K | Buy |
43
+5
| +13% | +$753 | ﹤0.01% | 363 |
|
|
2017
Q2 | $5K | Hold |
38
| – | – | ﹤0.01% | 390 |
|
|
2017
Q1 | $4K | Hold |
38
| – | – | ﹤0.01% | 382 |
|
|
2016
Q4 | $3K | Buy |
+38
| New | +$3.09K | ﹤0.01% | 442 |
|
Other funds holding VRTX
Arax Advisory Partners's VRTX Position: Q2 2026 in Review
Arax Advisory Partners increased its Vertex Pharmaceuticals (VRTX) stake by 228% in Q2 2026, buying an estimated $1.44M and bringing the position to 4,662 shares worth $2.32M. The position accounts for 0.02% of the portfolio, ranked #783.
Arax Advisory Partners first reported a position in VRTX in Q4 2016 and has held it in 37 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Arax Advisory Partners held 4,662 shares of Vertex Pharmaceuticals worth $2.32M as of Q2 2026.
- Arax Advisory Partners bought 3,239 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
- Vertex Pharmaceuticals made up 0.02% of Arax Advisory Partners's portfolio in Q2 2026, its #783 holding.
- Arax Advisory Partners first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.